Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model

American Journal of Ophthalmology

Volumn 145, Issue 3, 2008, Pages

  Papathanassiou, Miltiadis ^a   Theodossiadis, Panagiotis G ^a   Liarakos, Vasilios S ^a   Rouvas, Alexandros ^a   Giamarellos Bourboulis, Evaggelos J ^a   Vergados, Ioannis A ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BALANCED SALT SOLUTION; BEVACIZUMAB; SODIUM HYDROXIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RABBIT; RANK SUM TEST; SCAR FORMATION; SINGLE DRUG DOSE;

EID: 39149083043     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.11.003     Document Type: Article

References (34)

1. Chang J.H., Gabison E.E., Kato T., et al. Corneal neovascularization. Curr Opin Ophthalmol 12 (2001) 242-249
2. Cursiefen C., Kuchle M., and Naumann G.O. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 17 (1998) 611-613
3. Azar D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 104 (2006) 264-302
4. Dana M.R., Schaumberg D.A., Kowal V.O., et al. Corneal neovascularization after penetrating keratoplasty. Cornea 14 (1995) 604-609
5. Lee P., Wang C.C., and Adamis A.P. Ocular neovascularization: epidemiologic review. Surv Ophthalmol 43 (1998) 245-269
6. Koay P.Y., Lee W.H., and Figueiredo F.C. Opinions on risk factors and management of corneal graft rejection in the United Kingdom. Cornea 24 (2005) 292-296
7. Crum R., Szabo S., and Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230 (1985) 1375-1378
8. Joussen A.M., Kruse F.E., Volcker H.E., et al. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237 (1999) 920-927
9. Benelli U., Bocci G., Danesi R., et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res 67 (1998) 133-142
10. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
11. Phillips G.D., Stone A.M., Jones B.D., et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 8 (1994) 961-965
12. Gan L., Fagerholm P., and Palmblad J. Vascular endothelium growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82 (2004) 557-563
13. Philipp W., Speicher L., and Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41 (2000) 2514-2522
14. Adamis A.P., and Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina 25 (2005) 111-118
15. Zheng M., Deshpande S., Lee S., et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 75 (2001) 9828-9835
16. Mastyugin V., Mosaed S., Bonazzi A., et al. Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 23 (2001) 1-10
17. Zheng M., Schwarz M.A., Lee S., et al. Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 159 (2001) 1021-1029
18. Cursiefen C., Cao J., Chen L., et al. Inhibition of lymphagiogenesis and hemangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45 (2004) 2666-2673
19. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
20. Yang J.C., Haworth R.M., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
21. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
22. Moshfeghi A.A., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open label clinical study. Ophthalmology 113 (2006) 2002.e1-2002.e12
23. Bashshur Z.F., Bazarbachi A., Schakal A., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
24. Avery R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 352-354
25. Conners M.S., Urbano F., Vafeas C., Stoltz R.A., Dunn M.W., and Schwartzman M.L. Alkali burn-induced synthesis of inflammatory eicosanoids in rabbit corneal epithelium. Invest Ophthalmol Vis Sci 38 (1997) 1963-1971
26. Poulaki V., Mitsiades N., Kruse F.E., et al. Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression. Am J Pathol 164 (2004) 1293-1302
27. Masatoshi M., Shinji S., Saburo H., and Masayuki T. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 244 (2006) 205-209
28. Krachmer J.H., Mannis M.J., and Holland E.J. Alkali injuries of the eye, Chapter 103, Fig. 103.1: classification of alkali-burned eyes. In: Krachmer J.H., Mannis M.J., and Holland E.J. (Eds). Cornea. 2nd ed. Vol 1 (2005), Elsevier Mosby, Philadelphia, Pennsylvania 1288
29. Ma D.H., Tsai R.J., Chu W.K., et al. Inhibition of vascular endothelial cell morphogenesis in cultures by limbal epithelial cells. Invest Ophthalmol Vis Sci 40 (1999) 1822-1828
30. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., and Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (2007) 855-859
31. Cursiefen C., Rummelt C., and Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor α, and transforming growth factor β1 in human corneas with neovascularization. Cornea 19 (2000) 526-533
32. Manzano R.P., Peyman G.A., Khan P., et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91 (2007) 804-807
33. Destafeno J.J., and Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125 (2007) 834-836
34. Erdurmus M., and Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245 (2007) 1577-1579